Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
88 Results for "
BET PROTAC
" in MedChemExpress (MCE) Product Catalog:
Products (88)
88 Results for "BET PROTAC" in MCE Product Catalog:
Research Areas:
(+)-JQ-1-aldehyde is the aldehyde form of (+)-JQ1. (+)-JQ-1-aldehyde can be uesd as a precursor to synthesize PROTACs, which targets BET bromodomains .
Cat. No.: HY-160262
CAS No.: 2571123-81-2
Research Areas:
PROTAC AR/BET protein degrader-1 (Compound 149) is an Androgen Receptor and BET (bromodomain and extra-terminal domain) protein degrader that can be used in cancer research .
Cat. No.: HY-172562
CAS No.: 3093583-69-5
Research Areas:
BTR2004 is a potent and selective BET family (BRD2/3/4) PROTAC degrader, with EC50 values of 46, 87, and 777 nM, respectively. By bridging BET family proteins and the CUL3-KLHL20 E3 ubiquitin ligase, BTR2004 forms a ternary complex in the nucleus, thereby mediating the degradation of target proteins via the ubiquitin-proteasome system. BTR2004 can be used in research related to prostate cancer, breast cancer, colorectal cancer, osteosarcoma, and hepatocellular carcinoma .
Cat. No.: HY-135250A
CAS No.: 1957235-99-2
Research Areas:
Thalidomide-4-O-C6-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate used in the PROTAC dTAG-13 (HY-114421), a degrader of FKBP12 F36V and BET .
Synonyms: VH032-C10-NH2 dihydrochloride
Research Areas:
(S,R,S)-AHPC-C10-NH2 dihydrochloride (VH032-C10-NH2 dihydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for BET-Targeted PROTAC .
Cat. No.: HY-W1120221
CAS No.: 2093387-41-6
Research Areas:
Lenalidomide-C3-NH2 is an E3 ligase ligand-linker conjugate that incorporates the Lenalidomide (HY-A0003) based CRBN ligand (HY-43722) and linker. Lenalidomide-C3-NH2 can be used for synthesis of PROTAC BET degrader-2 (HY-114228) .
Cat. No.: HY-158331
CAS No.: 3055593-64-8
Research Areas:
Gal-ARV-771 is a galactose-modified derivative of ARV-771 (HY-100972). Gal-ARV-771 is activated in cells expressing SA-β-Gal, thereby releasing ARV-771. Gal-ARV-771 selectively induces Apoptosis. ARV-771 is a BET PROTAC degrader. Gal-ARV-771 can be used in the research of lung adenocarcinoma (Gal+linker: Gal-PAB (HY-188142); PROTAC: ARV-771 (HY-100972)) .
Cat. No.: HY-130814
CAS No.: 2093387-50-7
Research Areas:
Thalidomide-NH-C4-NH2 TFA (compound 29c) is an E3 ligase ligand-linker conjugate, and incorporates the Thalidomide based cereblon ligand and a linker. Thalidomide-NH-C4-NH2 TFA is used in PROTAC BRD2/BRD4 degrader-1 (HY-130612). PROTAC BRD2/BRD4 degrader-1 is a potent and selective BET protein BRD4 and BRD2 degrader .
Cat. No.: HY-170390
Target:
Research Areas:
AB3067 is a PROTAC degrader of BET that simultaneously recruits the E3 ligase activities of CRBN and VHL. The DC50 values of AB3067 against BRD2, BRD3, BRD4 Short and BRD4 Long are 15 nM, 1.6 nM, 2.1 nM and 2.3 nM, respectively. AB3067 induces additive protein ubiquitination and proteasomal degradation, and minimizes the cross-degradation of E3 ligases. AB3067 can be used in colon cancer-related studies .
Synonyms: (R)-Molibresib carboxylic acid; (R)-GSK525762A carboxylic acid; (R)-PROTAC BRD4-binding moiety 2
Research Areas:
(R)-I-BET762 carboxylic acid, the R-enantiomer of I-BET762 carboxylic acid (HY-107443). I-BET762 carboxylic acid is an I-BET762-based warhead ligand for conjugation reactions of PROTAC targeting on BET. I-BET762 carboxylic acid is a BRD4 inhibitor with a pIC50 value of 5.1 .
Cat. No.: HY-179588
Target:
Research Areas:
PROTAC BET Degrader-14 is a highly efficient PROTAC targeting BET (bromodomain and extra-terminal domain). PROTAC BET Degrader-14 can degrade all BET (BRD2, BRD3, BRD4) family proteins. PROTAC BET Degrader-14 potently degrades BET proteins in U2OS osteosarcoma cell lines (BRD4 DC50 = 130 nM) and KYSE180 esophageal squamous cell carcinoma cell lines (DC50 = 40 nM). PROTAC BET Degrader-14’s dependence on the ubiquitin-proteasome system. PROTAC BET Degrader-14 decreases levels of BET-regulated gene products c-Myc, RUNX2, and KRT14. PROTAC BET Degrader-14 can be used for the study of osteosarcoma .
Cat. No.: HY-103633R
CAS No.: 2093386-22-0
Research Areas:
PROTAC BET Degrader-1 (Standard) is the analytical standard of PROTAC BET Degrader-1 (HY-103633). This product is intended for research and analytical applications. PROTAC BET Degrader-1 is a BRD2/BRD3/BRD4 PROTAC degrader. PROTAC BET Degrader-1 inhibits the growth of acute leukemia cells. PROTAC BET Degrader-1 is applicable to the research of acute leukemia .
Cat. No.: HY-181867
CAS No.: 2410947-65-6
Target:
Research Areas:
PROTAC BET Degrader-16 (Compound A10) is a BET PROTAC degrader with a DC50 of 0.31 nM against BRD4, and it preferentially targets BRD4 over other BET family members. PROTAC BET Degrader-16 degrades BRD2, BRD3 and BRD4 via the ubiquitin-proteasome system, a process that requires target binding and recruitment of the CRBN E3 ligase. PROTAC BET Degrader-16 induces cell cycle arrest and promotes apoptosis. PROTAC BET Degrader-16 exerts anti-tumor activity against acute myeloid leukemia .
Cat. No.: HY-184335
CAS No.: 3097564-20-7
Research Areas:
PROTAC BET Degrader-18 is a PROTAC targeting BET, with a DC50 of 0.676 nM in HEK293-BRD4-HiBiT-KI cells. PROTAC BET Degrader-18 mainly targets and degrades BRD4 (EC50 = 59.91 nM), and exhibits weak degradation activity against BRD2. PROTAC BET Degrader-18 inhibits the expression of downstream oncoprotein c-Myc, thereby inducing cell cycle arrest and apoptosis, while suppressing oncoprotein expression. PROTAC BET Degrader-18 shows antiproliferative activity against acute myeloid leukemia cells and triple-negative breast cancer cells. PROTAC BET Degrader-18 demonstrates antitumor efficacy in xenograft mouse models. PROTAC BET Degrader-18 can be used for the research of acute myeloid leukemia and triple-negative breast cancer .
Cat. No.: HY-181729
PROTAC BET Degrader-15 is a BET PROTAC degrader with DC50 values of <0.10 nM, <0.01 nM, and <0.01 nM against BRD2, BRD3, and BRD4, respectively. PROTAC BET Degrader-15 induces significant G2/M phase cell cycle arrest and triggers apoptosis. PROTAC BET Degrader-15 causes marked downregulation of c-Myc, accompanied by upregulation of the cell cycle inhibitory protein p21, downregulation of CDK6, and an increase in the apoptosis marker cleaved PARP. PROTAC BET Degrader-15 is applicable to the research of hematologic malignancies and lung cancer .
Cat. No.: HY-181869
CAS No.: 2409674-38-8
Target:
Research Areas:
PROTAC BET Degrader-17 is a potent BET protein PROTAC degrader. By recruiting the VHL E3 ligase, PROTAC BET Degrader-17 specifically degrades BRD2, BRD3 (DC50=0.09 nM) and BRD4 (IC50=4.3 nM). PROTAC BET Degrader-17 exhibits strong anti-tumor activity in acute myeloid leukemia (AML) studies; it not only inhibits cancer cell proliferation, induces cell cycle arrest and apoptosis, but also effectively suppresses tumor growth in xenograft mouse models. PROTAC BET Degrader-17 can be used to explore targeted therapies for acute myeloid leukemia .
Cat. No.: HY-107451R
CAS No.: 2093387-77-8
Research Areas:
PROTAC BET-binding moiety 1 (Standard) is the analytical standard of PROTAC BET-binding moiety 1 (HY-107451). This product is intended for research and analytical applications. PROTAC BET-binding moiety 1 is a key intermediate for the synthesis of high-affinity BET inhibitors .
Cat. No.: HY-W584512
CAS No.: 2093386-23-1
Research Areas:
Thalidomide-NH-CH2-COO (t-Bu) is a ligand for E3 ubiquitin ligase PROTAC BET Degrader-1 (HY-103633) .
Cat. No.: HY-159076
CAS No.: 37630-54-9
Target:
Research Areas:
E3 ligase Ligand 7 (Compound 6) is a ligand for E3 ligase. E3 ligase Ligand 7 can be utilized for the synthesis of PROTAC BET Degrader-12 (HY-158764) .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
